Advances in prostate cancer early detection and‌ treatment have improved outcomes in men diagnosed wiht the disease. ⁢Yet, doctors and scientists have long been vexed by a‍ question: Why do most ‍men whose prostate cancer initially responds to hormonal-blocking therapy later develop a⁣ lethal, treatment-resistant form of the‍ disease?

Its a question that Ekta Khurana, associate⁢ professor of systems and computational biomedicine at ⁣Weill‍ Cornell ⁤Medicine, has been dedicated to‍ answering.‍ In May 2022, Khurana and her colleagues at Memorial ‍sloan Kettering Cancer center ‍were the first⁣ scientific ⁣team to identify four distinct subtypes⁣ of treatment-resistant prostate cancer, known as castration-resistant prostate‍ cancer (CRPC), along with the molecules that drive their growth. The discovery⁣ led to a better understanding of why the disease returns and opened avenues for more targeted therapies.

Understanding castration-Resistant Prostate Cancer

Prostate cancer is the most common ⁢cancer in American men, excluding skin‍ cancers. ⁤According to the American Cancer ⁤Society, about 1 in 8 men will be diagnosed with prostate cancer during their lifetime. ⁣ Initial treatment ⁢frequently enough involves ⁣androgen deprivation therapy (ADT), which blocks ‌the effects of testosterone, a hormone that fuels prostate cancer growth. However, most ⁢cancers eventually become resistant to ADT, ⁤progressing⁢ to CRPC, a far more aggressive‍ form of the disease. The American Cancer Society estimates that in 2024,‌ approximately 35,250 men⁣ will die from prostate cancer (American Cancer Society, 2024).

The Four Subtypes of CRPC

Khurana’s team used a ‍combination of genomic, transcriptomic, and proteomic data ⁣from hundreds of CRPC samples to define the subtypes. these subtypes aren’t simply defined by genetic mutations; they are characterized by distinct molecular signatures that influence how the cancer responds to different ‍treatments. ​The⁢ four subtypes are: